Company Encyclopedia
View More
name
HUA MEDICINE-B
02552.HK
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease.
1.450 T
02552.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking12/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE209.75%A
    • Profit Margin290.30%A
    • Gross Margin54.19%B
  • Growth ScoreA
    • Revenue YoY240.75%A
    • Net Profit YoY509.17%A
    • Total Assets YoY-12.59%E
    • Net Assets YoY3352.50%A
  • Cash ScoreB
    • Cash Flow Margin34.45%C
    • OCF YoY240.75%A
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreB
    • Gearing Ratio25.41%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hua Medicine Files Directors List to HKEX

    Hua Medicine has filed an updated list of directors and their roles with the Hong Kong Stock Exchange, effective November 27, 2025. The Board includes Executive Directors Mr. Li Chen, Mr. George Chien Cheng Lin, and Ms. Yi Zhang; Non-executive Director Mr. Robert Taylor Nelsen; and Independent Non-executive Directors Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui, and Mr. Yiu Leung Andy Cheung. Committee assignments are detailed in the filing.

    Reuters·
    HK
    02552
    -0.61%
    Reuters·
    HK
    02552
    -0.61%

    Hua Medicine Appoints Andy Cheung to Remuneration Committee

    Hua Medicine has appointed Mr. Yiu Leung Andy Cheung as a member of its Remuneration Committee. The committee now includes Mr. William Robert Keller (chairman), Mr. Yiu Wa Alec Tsui, and Mr. Cheung. His other board roles remain unchanged. This announcement was made via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    02552
    -0.61%
    Reuters·
    HK
    02552
    -0.61%

    Nona Bioscience appoints Hong Di as Chief Executive Officer

    On October 15th, Nona Bioscience announced the appointment of Hong Di as Chief Executive Officer. Hong Di will be based in Shanghai and report directly to Nona Bioscience Chairman Wang Jinsong. Prior to joining Nona Bioscience, he served as the Chief Executive Officer of Hillhouse Capital's life sciences infrastructure platform, GaoYue Group, and held senior management positions at HUA MEDICINE, Bouno-Sandia, Amgen, Eli Lilly, and Roche

    Zhitong·
    HK
    02552
    -0.61%
    Zhitong·
    HK
    02552
    -0.61%

    Hua Medicine Announces that the Pharmaceutical Service of Hong Kong Department of Health of China has Officially Accepted the Application for Marketing Authorization of the New Drug Dorzagliatin

    Hua Medicine announced that the Hong Kong Department of Health has accepted its New Drug Application (NDA) for dorzagliatin, the first glucokinase activator approved for Type 2 diabetes treatment. This acceptance marks a significant milestone in the company's strategy to expand into Southeast Asia and beyond. Dorzagliatin, which targets the root cause of blood sugar dysregulation, has shown promising results in clinical trials. The new approval mechanism in Hong Kong simplifies the registration process, positioning the region as a strategic gateway for Hua Medicine's global expansion.

    Asian Corporate Newswire·
    HK
    02552
    -0.61%
    Asian Corporate Newswire·
    HK
    02552
    -0.61%

    Hong Kong Stock Movement: HUA MEDICINE-B surged 14.25%

    HUA MEDICINE-B surged 14.25%; CSPC Pharmaceutical Group fell 3.38%, with a transaction volume of HKD 1.297 billion; China Biologic Products fell 2.78%, with a transaction volume of HKD 755 million; Heng Rui Medicine fell 7.51%, with a transaction volume of HKD 461 million; Hansoh Pharmaceutical fell 4.30%, with a market value of HKD 215.2 billion

    HK Stock Movers Tracker·
    HK
    02552
    -0.61%
    HK Stock Movers Tracker·
    HK
    02552
    -0.61%
    © 2025 Longbridge｜Disclaimer